Overview

Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

Status:
Active, not recruiting
Trial end date:
2022-12-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.
Phase:
Phase 3
Details
Lead Sponsor:
Allergan
Treatments:
Cariprazine